Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0028754
Disease: Obesity
Obesity
1.000 GeneticVariation disease BEFREE PPAR-γ gene polymorphism is associated with and increased the risk of psoriasis and its associated obesity in Egyptian patients. 31148857 2020
CUI: C0028754
Disease: Obesity
Obesity
1.000 AlteredExpression disease BEFREE PPARG mRNA expression decreased 32% (P = 0.044) in adipocytes from individuals with obesity. 31531958 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 AlteredExpression disease BEFREE Identification of the factors that regulate PPARγ expression and activity is therefore crucial for combating obesity. 31653699 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 AlteredExpression disease BEFREE However, the expression of PPARγ is reduced by obesity and several nutritional factors. 30348686 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 Biomarker disease BEFREE PD improved obesity in db/db mice by AMPK-associated decrease of adipogenic markers including PPARγ and C/EBPα. 30599906 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 GeneticVariation disease BEFREE The PPARG rs1801282 (G/C) polymorphism has been associated with OSA in obese Indian subjects, whereas no such association has been reported in Chinese Han subjects. 31044373 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 Biomarker disease BEFREE An involvement of FABP4 in the pathogenesis of obesity and insulin resistance seems to be mediated via FABP4-dependent peroxisome proliferator-activated receptor γ (PPARγ) inhibition. 30857223 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 Biomarker disease BEFREE These results conclude that the BGE extract containing several kinds of polymethoxy flavones showed PPARγ ligand-binding capacity in vitro and prevented obesity and insulin resistance independent of adiponectin secretion in mice. 30726580 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 Biomarker disease BEFREE These tool analysed and found 4 RNAs gene knock out possibilities in PPARγ and their efficiency for further treating obesity. 31152927 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 Biomarker disease BEFREE Agaricus bisporus-derived β-glucan prevents obesity through PPAR γ downregulation and autophagy induction in zebrafish fed by chicken egg yolk. 30557642 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 AlteredExpression disease BEFREE VDR and PPARγ mRNA expression was higher in the adipose tissues of GDM women in comparison to that of women with normal glucose tolerance (VDR mRNA: G1 vs. N1: 210.00 [90.58-311.46] vs. 89.34 [63.74-159.92], G2 vs. N2: 298.67 [170.84-451.25] vs. 198.28 [119.46-261.23], PPARγ mRNA: G1 vs. N1: 100.72 [88.61-123.87] vs. 87.52 [66.37-100.04], G2 vs. N2: 117.33 [100.08-149.00] vs. 89.90 [76.95-109.09], P < 0.05), and their expression was the highest in GDM + overweight/obese women. 31651513 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 Biomarker disease BEFREE These findings indicate that HSPA12A is a novel regulator of adipocyte differentiation and diet-induced obesity through a positive feedback regulation with PPARγ. 30742088 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 AlteredExpression disease BEFREE These results suggest that the combined regulation of PPARγ, SMAD and the adrenergic receptor signalling pathway synergistically induces brown adipogenesis and may serve as an effective strategy to treat obesity and related diseases, including type 2 diabetes. 31317231 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 Biomarker disease BEFREE Loss of μ-crystallin causes PPARγ activation and obesity in high-fat diet-fed mice. 30545633 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 Biomarker disease BEFREE Obesity rats induced by 8-week high fat diet (HFD) were randomly divided into obesity group (OB) and exercised obesity group (EOB) with 8 rats each group, and 40 diabetes rats established by 8-week HFD plus low dose of streptozotocin were randomly divided into 4 groups: diabetes group (DM), exercised diabetes group (EDM), exercised diabetes plus PPARγ agonist pioglitazone group (EDP), and exercised diabetes plus PPARγ antagonist GW9662 group (EDG). 30873215 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 Biomarker disease BEFREE Thus, PPARγ agonists are of -interest in the therapeutic approach to treat CKD in the context of obesity. 30625473 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 Biomarker disease BEFREE Here we dissected the specific role of high-fat-diet (HFD)-induced obesity and vascular smooth muscle cell (VSMC)-PPARγ for remodelling of small pulmonary arteries. 30813929 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 Biomarker disease BEFREE It was found that resistin expression is significantly correlated with lipid profile and inflammatory status in obesity and atherosclerotic groups, and PPARγ agonist administration significantly improves inflammatory status and dyslipidemic profile across studied groups (p < .05). 30612469 2019
CUI: C0028754
Disease: Obesity
Obesity
1.000 GeneticVariation disease BEFREE We further show that in the context of diet-induced obesity PPARγ-K107R-mutant mice have enhanced insulin sensitivity without the corresponding increase in adiposity that typically accompanies PPARγ activation by TZDs. 30420515 2018
CUI: C0028754
Disease: Obesity
Obesity
1.000 Biomarker disease BEFREE MiR-27a derived from these adipocytes induced insulin resistance in C2C12 skeletal muscle cells through miR-27a-mediated repression of PPARγ and its downstream genes involved in the development of obesity. 29721071 2018
CUI: C0028754
Disease: Obesity
Obesity
1.000 Biomarker disease BEFREE These results suggest that CD38 deficiency impairs adipogenesis and lipogenesis through activating Sirt1/PPARγ-FASN signalling pathway during the development of obesity. 28816006 2018
CUI: C0028754
Disease: Obesity
Obesity
1.000 GeneticVariation disease BEFREE Here, we show that targeted PPARγ mutations resulting in constitutive deacetylation (K268R/K293R, 2KR) increased energy expenditure and protected from visceral adiposity and diet-induced obesity by augmenting brown remodeling of white adipose tissues. 29589839 2018
CUI: C0028754
Disease: Obesity
Obesity
1.000 Biomarker disease BEFREE An interaction between ERRα and peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) has also recently been shown to regulate an enzyme in the β-oxidation of free fatty acids, thereby suggesting that ERRα plays an important role in obesity and type 2 diabetes. 29216352 2018
CUI: C0028754
Disease: Obesity
Obesity
1.000 Biomarker disease BEFREE Peroxisome proliferator activated receptor-gamma (PPAR-γ) is implicated in several metabolic syndromes including Diabetic Nephropathy, besides obesity, insulin insensitivity, dislipidemia, inflammation, and hypertension. 28539091 2018
CUI: C0028754
Disease: Obesity
Obesity
1.000 Biomarker disease BEFREE Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ). 30463189 2018